{"id":57438,"date":"2023-05-19T04:03:16","date_gmt":"2023-05-19T02:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/"},"modified":"2023-05-19T04:03:16","modified_gmt":"2023-05-19T02:03:16","slug":"agilent-to-appeal-patent-office-decision-on-crispr-grna-patents","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/","title":{"rendered":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents"},"content":{"rendered":"
\n

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board\u2019s (PTAB) Final Written Decision in connection with the Inter Partes<\/i> review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO\u2019s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.<\/p>\n

<\/a><\/p>\n

\nAgilent respectfully disagrees with the PTAB\u2019s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination. The work presented in the two Agilent Patents is also discussed in a publication as part of a broader collaboration with Stanford University in the widely cited paper: Hendel, Ayal et al. \u201cChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.\u201d Nature biotechnology vol. 33,9 (2015): 985-989. doi:10.1038\/nbt.3290.<\/p>\n

\nThe Agilent Patents describe synthesis and testing of hundreds of chemically modified CRISPR guide RNA molecules that were shown to improve the efficiency of CRISPR-based gene editing. Prior to the work done by Agilent\u2019s inventors, it was not known whether the many chemical modifications Agilent made to the various and long guide RNAs would disrupt functionality of the gRNA:Cas enzyme complex. That answer was discovered and disclosed by the Agilent inventors as a multidisciplinary team and using Agilent\u2019s own patented chemical synthesis methods.<\/p>\n

\nBuilding upon its years of expertise in nucleic acid synthesis, Agilent offers the scientific community both research-grade and cGMP-grade guide RNA products incorporating chemical modifications. Agilent\u2019s SureGuide research-grade gRNA products are made and sold in Agilent\u2019s production facility in Santa Clara, California. Agilent\u2019s Nucleic Acid Solutions Division makes and sells its large-scale, cGMP-grade ClinGuide products in its state-of-the art production facilities headquartered in Boulder, Colorado.<\/p>\n

\nAgilent is confident in the innovative contributions made by its scientists and intends to appeal to the United States Court of Appeals for the Federal Circuit. This patent family also remains open with ongoing prosecution of new claims. Agilent\u2019s Patents will persist until all appeals have been exhausted, and the PTAB decision does not affect Agilent\u2019s continued leadership in CRISPR technologies as a provider of superior-quality guide RNAs. The PTAB\u2019s decision in no way affects Agilent\u2019s ability to make or sell chemically modified gRNA guides.<\/p>\n

\nAbout Agilent Technologies<\/b><\/p>\n

\nAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent\u2019s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com<\/a>. To receive the latest Agilent news, subscribe to the Agilent Newsroom<\/a>. Follow Agilent on LinkedIn<\/a> and Facebook<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR CONTACT:
\n
Parmeet Ahuja
\n
+1 408 345 8948
\n
Parmeet_Ahuja@agilent.com<\/a><\/p>\n

\nMEDIA CONTACT:
\n
Sarah Litton
\n
Agilent Technologies
\n
+1 669 255 7696
\n
sarah.litton@agilent.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board\u2019s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57438","6":"format-standard","7":"category-industry"},"yoast_head":"\nAgilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board\u2019s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-19T02:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents\",\"datePublished\":\"2023-05-19T02:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/\"},\"wordCount\":509,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230518005808\\\/en\\\/738858\\\/21\\\/Logo-Agilent.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/\",\"name\":\"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230518005808\\\/en\\\/738858\\\/21\\\/Logo-Agilent.jpg\",\"datePublished\":\"2023-05-19T02:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230518005808\\\/en\\\/738858\\\/21\\\/Logo-Agilent.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230518005808\\\/en\\\/738858\\\/21\\\/Logo-Agilent.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/","og_locale":"en_US","og_type":"article","og_title":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend","og_description":"SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board\u2019s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-19T02:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents","datePublished":"2023-05-19T02:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/"},"wordCount":509,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/","url":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/","name":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg","datePublished":"2023-05-19T02:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230518005808\/en\/738858\/21\/Logo-Agilent.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/agilent-to-appeal-patent-office-decision-on-crispr-grna-patents\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57438"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57438\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}